CWC Advisors LLC. Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

CWC Advisors LLC. bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 16,150 shares of the biopharmaceutical company’s stock, valued at approximately $378,000.

Several other hedge funds also recently bought and sold shares of TGTX. Vanguard Group Inc. raised its holdings in TG Therapeutics by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 13,670,944 shares of the biopharmaceutical company’s stock worth $233,500,000 after purchasing an additional 199,770 shares during the period. Hennion & Walsh Asset Management Inc. raised its holdings in TG Therapeutics by 16.9% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 184,815 shares of the biopharmaceutical company’s stock worth $2,811,000 after purchasing an additional 26,761 shares during the period. Principal Financial Group Inc. raised its holdings in TG Therapeutics by 3.9% in the first quarter. Principal Financial Group Inc. now owns 35,374 shares of the biopharmaceutical company’s stock worth $538,000 after purchasing an additional 1,322 shares during the period. Swiss National Bank raised its holdings in TG Therapeutics by 0.5% in the first quarter. Swiss National Bank now owns 284,100 shares of the biopharmaceutical company’s stock worth $4,321,000 after purchasing an additional 1,500 shares during the period. Finally, Quantum Private Wealth LLC raised its holdings in TG Therapeutics by 13.7% in the first quarter. Quantum Private Wealth LLC now owns 103,604 shares of the biopharmaceutical company’s stock worth $1,576,000 after purchasing an additional 12,523 shares during the period. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Stock Up 0.6 %

Shares of TGTX stock opened at $23.36 on Friday. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58. TG Therapeutics, Inc. has a 1 year low of $6.89 and a 1 year high of $26.41. The firm’s fifty day moving average price is $23.44 and its two-hundred day moving average price is $19.63. The firm has a market capitalization of $3.61 billion, a P/E ratio of 101.57 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.08. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The firm had revenue of $73.47 million for the quarter, compared to analyst estimates of $65.92 million. During the same period in the previous year, the business earned ($0.34) EPS. The company’s revenue was up 357.0% compared to the same quarter last year. On average, equities analysts predict that TG Therapeutics, Inc. will post 0.13 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on TGTX shares. The Goldman Sachs Group raised their price objective on shares of TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and set a $49.00 price objective on shares of TG Therapeutics in a report on Wednesday, September 18th. Finally, B. Riley raised their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, TG Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $31.83.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.